Now Playing
|Videos|December 15, 2022
Introduction to the HR+ Treatment Landscape
Virginia Kaklamani, MD and Heather McArthur, MD begin by discussing new data regarding the use of aromatase inhibitors and ovarian function suppression in women with HR+ early breast cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Neil Mehta, MD, and Laura Kulik, MD, discussed patient selection, washout timing, and posttransplant monitoring for immunotherapy before liver transplant.
Andrew Moon, MD, MPH, explained how liver function, biomarkers, and patient preferences should shape multidisciplinary treatment decisions in HCC.
Hashem B. El-Serag, MD, MPH, said HCC risk in MASLD centers on advanced fibrosis and cirrhosis, while extrahepatic cancers warrant routine screening.
More than half of patients with microsatellite-stable metastatic colorectal cancer without active liver metastases survived at least 18 months with botensilimab plus balstilimab.
Investigators will present detailed findings from a phase 2 study assessing a tambiciclib-based regimen in patients with relapsed/refractory AML at ASH 2026.
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.
Chinmay Jani, MD, discusses ASCO 2026 data on lung cancer trends in younger adults and why this group has been overlooked.
Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
3
Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC
4
Where Does Prostate Brachytherapy Fit Best in the Treatment Paradigm?
5